首页> 美国卫生研究院文献>Journal of Clinical Medicine >Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic
【2h】

Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic

机译:IBD患者的口服铁剂:COVID-19大流行时的经验教训

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Anemia is a frequent manifestation in patients with chronic inflammatory bowel disease (IBD) and requires tight monitoring and adequate supplementary therapy. Intravenous iron is the first-line treatment in subjects with moderate–severe anemia, active disease, or oral iron intolerance. On the other hand, oral iron is recommended in patients with mild anemia and inactive disease. However, during the current coronavirus pandemic, hospital activities have significantly changed, and all non-essential procedures, including non-urgent iron infusions, have been rescheduled. Oral iron, including both the traditional formulations with ferrous iron and the new ferric iron complexes, could constitute a valid alternative for anemia treatment. For this reason, we conducted a literature review, to summarize the scientific evidence on oral iron therapy in IBD patients with anemia.
机译:贫血是慢性炎症性肠病(IBD)患者的常见表现,需要严密监控和适当的辅助治疗。静脉铁剂是患有中度至重度贫血,活动性疾病或口服铁不耐受的受试者的一线治疗。另一方面,轻度贫血和非活动性疾病的患者建议口服铁剂。但是,在当前的冠状病毒大流行期间,医院的活动已发生了显着变化,所有非必要的程序,包括非紧急的铁输注,都已重新安排。口服铁,包括传统的含二价铁配方和新的三价铁配合物,都可以构成贫血治疗的有效替代方案。因此,我们进行了文献综述,总结了IBD贫血患者口服铁疗法的科学依据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号